Welcome to
Sysmex Flow Cytometry Other European Country!

For ordering please make sure you are in your local shop.
If you are from Other European Country then please continue.
Otherwise please go to your country.

Go to my country Continue

Article successfully added.

CyFlow™ CD34 PE-Cy5

CyFlow™ CD34 PE-Cy5
Antigen: CD34
Clone: 581
Application: Flow cytometry
Format/Fluorochrome: PE-Cy5
Laser: Blue, Green, Yellow
Target Species: Human, Non-Human Primates
Field of Interest: Immunophenotyping
Species of Origin: Mouse
Regulatory Status: RUO
Clonality: monoclonal
Emission Maximum: 670 nm
Excitation Maximum: 496 nm, 565 nm
Isotype: IgG1
Order number: AG891077

For Research Use Only
Not for use in diagnostic or therapeutic procedures.

Quantity 100 tests Volume 0.4 Immunogen Background Information CD34... more
CyFlow™ CD34 PE-Cy5
Quantity100 tests
Immunogen< no data >
Background InformationCD34 (Mucosialin) is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montaño J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR: Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999·May·15; 93(10):3379‑90. <·PMID:·10233890·> | Ando K, Nakamura Y, Chargui J, Matsuzawa H, Tsuji T, Kato S, Hotta T: Extensive generation of human cord blood CD34(+) stem cells from Lin(‑)CD34(‑) cells in a long‑term in vitro system. Exp·Hematol. 2000·Jun; 28(6):690‑9. <·PMID:·10880755·> | Felschow DM, McVeigh ML, Hoehn GT, Civin CI, Fackler MJ: The adapter protein CrkL associates with CD34. Blood. 2001·Jun·15; 97(12):3768‑75. <·PMID:·11389015·> | Kato S, Ando K, Nakamura Y, Muguruma Y, Sato T, Yabe H, Yabe M, Hattori K, Yasuda Y, Hotta T: Absence of a CD34‑ hematopoietic precursor population in recipients of CD34+ stem cell transplantation. Bone·Marrow·Transplant. 2001·Sep; 28(6):587‑95. <·PMID:·11607772·> | Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A: CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, andnormal bone marrow display different apoptosis and drug resistance‑associated phenotypes. Clin·Cancer·Res. 2004·Nov·15; 10(22):7599‑606. <·PMID:·15569991·> | Ono F, Sharma BK, Smith CC, Burnett JW, Aurelian L: CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM).. J·Invest·Dermatol. 2005·Jun; 124(6):1215‑24. <·PMID:·15955097·> | Ninos JM, Jefferies LC, Cogle CR, Kerr WG: The thrombopoietin receptor, c‑Mpl, is a selective surface marker for human hematopoietic stem cells. J·Transl·Med. 2006·Feb·16; 4:9. <·PMID:·16480521·> | Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T: Dose‑dependent contribution of CD34‑positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery aftr myocardial infarction. Circulation. 2006·Mar·14; 113(10):1311‑25. <·PMID:·16534028·> | Goardon N, Nikolousis E, Sternberg A, Chu WK, Craddock C, Richardson P, Benson R, Drayson M, Standen G, Vyas P, Freeman S: Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica. 2009·Aug; 94(8):1160‑3. <·PMID:·19644143·> | Sanz E, Muñoz-A N, Monserrat J, Van-Den-Rym A, Escoll P, Ranz I, Alvarez-Mon M, de-la-Hera A: Ordering human CD34+CD10‑CD19+ pre/pro‑B‑cell and CD19‑ common lymphoid progenitor stages in two pro‑B‑cell development pathways. Proc·Natl·Acad·Sci·USA. 2010·Mar·30; 107(13):5925‑30. <·PMID:·20231472·>